# A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors

> **NCT05946226** · PHASE1 · UNKNOWN · sponsor: **Suzhou Immunofoco Biotechnology Co., Ltd** · enrollment: 18 (estimated)

## Conditions studied

- Advanced Digestive System Tumor

## Interventions

- **BIOLOGICAL:** IMC002 injection

## Key facts

- **NCT ID:** NCT05946226
- **Lead sponsor:** Suzhou Immunofoco Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-07
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05946226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05946226, "A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05946226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*